Comprehensive Pharmacogenetic Genotyping Panel

 

Related Gene(s): ABCB1, ABCG2, ADRA2A, COMT, CYP1A2, CYP2B6, CYP2C (rs12777823), CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP4F2, DPYD, DRD2, F2, F5, G6PD, GRIK4, HTR2A, HTR2C, NUDT15, OPRM1, SLCO1B1, TPMT, UGT1A1, UGT2B15, VKORC1

Related Medication(s): Please see the Pharmacogenetic Medication and Gene Panels table for further information

Our Comprehensive Pharmacogenetic Genotyping Panel is designed to detect allelic and copy number variants in 29 drug response genes that are clinically actionable or informative on over 162 medications. This test is intended to help physicians make therapeutic decisions for these selected medications that can have interindividual response variability. In addition, this panel also reports on thrombophilia risk by interrogating the F2 and F5 genes

For this test, targeted genotyping of functional sequence variants is performed using the Agena Biosciences platform and copy number variants interrogated for the CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, and CYP3A5 genes by MLPA. In addition, the UGT1A1*28 dinucleotide repeat allele is genotyped by PCR and capillary electrophoresis.

---

---